Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $19.4 million.

  • Arrowhead Pharmaceuticals' Share-based Compensation rose 2736.54% to $19.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $67.5 million, marking a year-over-year decrease of 281.36%. This contributed to the annual value of $63.4 million for FY2025, which is 1433.32% down from last year.
  • Arrowhead Pharmaceuticals' Share-based Compensation amounted to $19.4 million in Q4 2025, which was up 2736.54% from $19.1 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Share-based Compensation ranged from a high of $34.6 million in Q3 2021 and a low of $13.0 million during Q2 2025
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Share-based Compensation value was $19.4 million (recorded in 2022), while the average stood at $21.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 20088.41% in 2021, then tumbled by 4026.06% in 2023.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Share-based Compensation stood at $24.5 million in 2021, then decreased by 20.87% to $19.4 million in 2022, then increased by 1.57% to $19.7 million in 2023, then fell by 22.77% to $15.2 million in 2024, then grew by 27.37% to $19.4 million in 2025.
  • Its last three reported values are $19.4 million in Q4 2025, $19.1 million for Q3 2025, and $13.0 million during Q2 2025.